Is treat-to-target really working in rheumatoid arthritis? A longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)
- Ramiro, Sofia
- Landewé, Robert Bm
- van Der Heijde, Désirée
- Sepriano, Alexandre
- Fitzgerald, Oliver
- Ostergaard, Mikkel
- Homik, Joanne
- Elkayam, Ori
- Thorne, J Carter
- Larche, Margaret
- Ferraccioli, Gianfranco
- Backhaus, Marina
- Boire, Gilles
- Combe, Bernard
- Schaeverbeke, Thierry
- Saraux, Alain
- Dougados, Maxime
- Rossini, Maurizio
- Govoni, Marcello
- Sinigaglia, Luigi
- Cantagrel, Alain
- Allaart, Cornelia
- Barnabe, Cheryl
- Bingham, Clifton
- Tak, Paul
- van Schaardenburg, Dirkjan
- Hammer, Hilde Berner
- Dadashova, Rana
- Hutchings, Edna
- Paschke, Joel
- Maksymowych, Walter
DOIAbstract
International audienceObjectives To investigate whether following a treat-to-target (T2T)-strategy in daily clinical practice leads to more patients with rheumatoid arthritis (RA) meeting the remission target. Methods RA patients from 10 countries starting/changing conventional synthetic or biological disease-modifying anti-rheumatic drugs were assessed for disease activity every 3 months for 2 years (RA BIODAM (BIOmarkers of joint DAMage) cohort). Per visit was decided whether a patient was treated according to a T2T-strategy with 44-joint disease activity score (DAS44) remission (DAS44 <1.6) as the target. Sustained T2T was defined as T2T followed in ≥2 consecutive visits. The main outcome was the achievement of DAS44 remission at the sub...
Add to ORKG